GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (XTER:PV3) » Definitions » Goodwill-to-Asset

EyePoint Pharmaceuticals (XTER:PV3) Goodwill-to-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is EyePoint Pharmaceuticals Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. EyePoint Pharmaceuticals's Goodwill for the quarter that ended in Dec. 2023 was €0.00 Mil. EyePoint Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was €325.70 Mil. Therefore, EyePoint Pharmaceuticals's Goodwill to Asset Ratio for the quarter that ended in Dec. 2023 was 0.00.


EyePoint Pharmaceuticals Goodwill-to-Asset Historical Data

The historical data trend for EyePoint Pharmaceuticals's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Goodwill-to-Asset Chart

EyePoint Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

EyePoint Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of EyePoint Pharmaceuticals's Goodwill-to-Asset

For the Biotechnology subindustry, EyePoint Pharmaceuticals's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EyePoint Pharmaceuticals's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's Goodwill-to-Asset falls into.



EyePoint Pharmaceuticals Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

EyePoint Pharmaceuticals's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Goodwill to Asset (A: Dec. 2023 )=Goodwill/Total Assets
=0/325.704
=0.00

EyePoint Pharmaceuticals's Goodwill to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Goodwill to Asset (Q: Dec. 2023 )=Goodwill/Total Assets
=0/325.704
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EyePoint Pharmaceuticals  (XTER:PV3) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


EyePoint Pharmaceuticals Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


EyePoint Pharmaceuticals (XTER:PV3) Business Description

Traded in Other Exchanges
Address
480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (XTER:PV3) Headlines

No Headlines